scholarly journals Case report: intermittent fasting and probiotic yogurt consumption are associated with reduction of serum alpha-N-acetylgalactosaminidase and increased urinary excretion of lipophilic toxicants

2017 ◽  
Author(s):  
Jerry Blythe ◽  
Marco Ruggiero ◽  
Stefania Pacini
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Urinary Excretion ◽  
Immune Modulation ◽  
Thyroid Stimulating Hormone ◽  
Lymphocytic Leukemia ◽  
Intermittent Fasting ◽  
Probiotic Yogurt ◽  
Hydroxyisobutyric Acid ◽  
2,4 Dichlorophenoxyacetic Acid ◽  
Stimulating Hormone

AbstractIn this study, we describe the changes associated with three months of intermittent fasting and probiotic yogurt consumption in a 72-year-old marathon runner with chronic lymphocytic leukemia for a number of years. Serum alpha-N-acetylgalactosaminidase (nagalase), a marker of inflammation and cancer cell proliferation, was significantly decreased at the end of a three-month observation. These results are consistent with immune modulating properties of certain probiotics based on the fermentation of milk and colostrum. Urinary excretion of non-metal toxicants that accumulate in adipose tissue such as Perchlorate, N-acetyl(2-hydroxypropyl)cysteine (NAHP), 2,4-Dichlorophenoxyacetic acid, 3-Phenoxybenzoic acid (3PBA), N-acetyl phenyl cysteine (NAP), Phenylglycoxylic acid (PGO), Monoethylphthalate (MEP) and 2-Hydroxyisobutyric Acid (2HIB) was significantly increased. These results are consistent with the weight loss (5 Kg) associated with intermittent fasting and with the known features of probiotics as detoxification tools. Consistent with certain toxicants acting as endocrine disruptors, we observed an increased elimination of toxicants and a 33% decrease of serum Thyroid Stimulating Hormone (TSH), suggesting a trend toward normalization of thyroid function. These results support the hypothesis that a combination of intermittent fasting with the consumption of specific probiotic yogurts may lead to immune modulation, detoxification and other improvements.Abbreviations(NAHP)N-acetyl(2-hydroxypropyl)cysteine(3PBA)3-Phenoxybenzoic acid(NAP)Nacetyl phenyl cysteine(PGO)Phenylglycoxylic acid(MEP)Monoethylphthalate(2HIB)2-Hydroxyisobutyric Acid(TSH)Thyroid Stimulating Hormone(Dr. JB)Dr. Jerry Blythe(CLL)chronic lymphocytic leukemia(IRB)Institutional Review Board(GcMAF)Gc protein-derived Macrophage Activating Factor

Allotransplantation for chronic lymphocytic leukemia

Hematology ◽  
2009 ◽  
Vol 2009 (1) ◽  
pp. 602-609 ◽  
Author(s):  
Peter Dreger
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Immune Modulation ◽  
Residual Disease ◽  
Treatment Strategies ◽  
Treatment Resistance ◽  
Lymphocytic Leukemia ◽  
Successful Outcome ◽  
Mortality And Morbidity ◽  
Poor Risk ◽  
Leukemic Clone

AbstractEfforts to develop curative treatment strategies for chronic lymphocytic leukemia (CLL) in recent years have focused on allogeneic stem cell transplantation (alloSCT). The crucial anti-leukemic principle of alloSCT in CLL appears to be the immune-mediated anti-host activities conferred with the graft (graft-versus-leukemia effects, GVL). Evidence for GVL in CLL is provided by studies analyzing the kinetics of minimal residual disease on response to immune modulation after transplantation, suggesting that GVL can result in complete and durable suppression of the leukemic clone. AlloSCT from matched related or unrelated donors can overcome the treatment resistance of poor-risk CLL, ie, purine analogue refractory disease and CLL with del 17p-. Even with reduced-intensity conditioning, alloSCT in CLL is associated with significant mortality and morbidity due to graft-versus-host disease, which has to be weighed against the risk of the disease when defining the indication for transplantation. Therefore, it can be regarded as a reasonable treatment option only for eligible patients who fulfill accepted criteria for poor-risk disease. If alloSCT is considered, it should be performed before CLL has advanced to a status of complete refractoriness to assure an optimum chance for a successful outcome. Prospective trials are underway to prove whether allo-SCT can indeed change the natural history of poor-risk CLL.

scholarly journals The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

Blood ◽  
2011 ◽  
Vol 117 (16) ◽  
pp. 4323-4327 ◽  
Author(s):  
Sarah E. M. Herman ◽  
Rosa Lapalombella ◽  
Amber L. Gordon ◽  
Asha Ramanunni ◽  
Kristie A. Blum ◽  
...  
Keyword(s):  
B Cells ◽  
Growth Factor ◽  
Chronic Lymphocytic Leukemia ◽  
Immune Modulation ◽  
Cell Activation ◽  
Costimulatory Molecule ◽  
Immunoglobulin M ◽  
Lymphocytic Leukemia ◽  
Phosphatidylinositol 3 Kinase ◽  
Phosphatidylinositol 3

Abstract In patients with chronic lymphocytic leukemia (CLL), lenalidomide can promote humoral immune responses but also induces a distinct disease-specific toxicity of tumor flare and cytokine release. These CLL-specific events result from increased expression of costimulatory molecules on B cells. Here we demonstrate that lenalidomide activation of CLL cells depends on the phosphatidylinositol 3-kinase p110δ (PI3K-δ) pathway. Inhibition of PI3K-δ signaling by the PI3K-δ-inhibiting drug, CAL-101, or by siRNA knockdown of p110δ, abrogates CLL cell activation, costimulatory molecule expression, and vascular endothelial growth factor and basic fibroblast growth factor gene expression that is induced by lenalidomide. In addition, CAL-101 attenuates lenalidomide-mediated increases in immunoglobulin M production by normal B cells. Collectively, these data demonstrate the importance of PI3K-δ signaling for lenalidomide immune modulation. These findings may guide development of strategies for the treatment of CLL that combine lenalidomide with CAL-101, with other inhibitors of the PI3K-δ pathway, or with other agents that target downstream kinases of this signaling pathway.

scholarly journals Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic

2021 ◽  
pp. 1-11
Author(s):  
Petra Langerbeins ◽  
Barbara Eichhorst
Keyword(s):  
Immune System ◽  
Chronic Lymphocytic Leukemia ◽  
Immune Modulation ◽  
Treatment Initiation ◽  
Immune Dysfunction ◽  
Infectious Complications ◽  
Current Data ◽  
Lymphocytic Leukemia ◽  
The Novel ◽  
Severe Infections

The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has been first described in December 2019 in Wuhan, China, and has led to a worldwide pandemic ever since. Initial clinical data imply that cancer patients are particularly at risk for a severe course of SARS-CoV-2. In patients with chronic lymphocytic leukemia (CLL), infections are a main contributor to morbidity and mortality driven by an impaired immune system. Treatment initiation is likely to induce immune modulation that further increases the risk for severe infections. This article aims to give an overview on pathogenesis and risk of infectious complications in patients with CLL. In this context, we discuss current data of SARS-CoV-2 infections in patients with CLL and how the pandemic impacts their management.

scholarly journals Production of Severe Iodine Deficiency in Sheep Using a Prepared Low-Iodine Diet

1980 ◽  
Vol 33 (1) ◽  
pp. 53 ◽  
Author(s):  
BJ Potter ◽  
GB Jones ◽  
RA Buckley ◽  
GB Belling ◽  
GH McIntosh ◽  
...  
Keyword(s):  
Urinary Excretion ◽  
Blood Plasma ◽  
Iodine Deficiency ◽  
Thyroid Stimulating Hormone ◽  
Deficient Diet ◽  
Low Levels ◽  
In Blood Plasma ◽  
Stimulating Hormone

Extensive tests on dietary materials suitable for ingestion by sheep have led to the preparation of an appropriate diet which, when fed to the sheep, caused severe iodine deficiency. The deficiency was manifested by daily urinary excretion values which fell to levels of less than 20 pg iodine and by thyroxine (T4) and triiodothyronine (T3) concentrations in blood plasma which were reduced from more than 90 and 1�80 nmol/l to the low levels of less than 2�58 and 0�31 nmol/l respectively. The values were attained 5 months after feeding the low-iodine diet. Goitre was present in most of the animals and the reductions in T4 and T3 values were accompanied by increased concentrations of plasma thyroid stimulating hormone (TSH) from less than 8�6 to more than 68 ng/ml. Samples of wool removed from selected areas of the sheep showed that the iodine-deficient diet also caused a reduction in the growth of wool.

CONCENTRATIONS OF IMMUNOREACTIVE THYROTROPHIC HORMONE IN URINE OF NORMAL SUBJECTS, PATIENTS WITH THYROID DISORDERS AND HYPOPITUITARISM, AND AFTER INFUSION OF HUMAN THYROTROPHIC HORMONE

1974 ◽  
Vol 62 (3) ◽  
pp. 645-655 ◽  
Author(s):  
S. F. KUKU ◽  
P. HARSOULIS ◽  
J. L. YOUNG ◽  
T. R. FRASER
Keyword(s):  
Urinary Excretion ◽  
Diurnal Variation ◽  
Normal Subjects ◽  
Thyroid Stimulating Hormone ◽  
Thyroid Disorders ◽  
Human Pituitary ◽  
Double Antibody ◽  
Thyrotrophic Hormone ◽  
Stimulating Hormone

SUMMARY The urinary excretion of thyroid-stimulating hormone (TSH) has been measured by double antibody radioimmunoassay after concentration by dialysis followed by lyophilization. Among 30 normal subjects, the excretion was 5·6 ± 0·31 (s.e.m.) μu./h. No diurnal variation nor differences between sexes were discerned. In 14 primary hypothyroid subjects the urinary excretion was raised (P < 0·001) to 25·1 ± 3·3 μu./h. In 14 hyperthyroid and 7 hypopituitary subjects subnormal levels of 2·6 ± 0·2 and 2·5 ± 0·22 μu./h (P < 0·001) respectively, were found. Serum and urinary TSH concentrations were measured before, during and after an infusion of human pituitary TSH (MRC 70/9) in two subjects and showed a correlation. Urinary TSH measurement is thus a good discriminant between normal and hyperthyroid or hypopituitary patients.

Sign in / Sign up

Export Citation Format

Share Document